Table 1.
Model parameters
| Variable | Baseline value | Range | References | |
|---|---|---|---|---|
| Minimum | Maximum | |||
| NI: Log-normal PFS survival mode | λ = 1.93843, γ = 1.26135 | – | – | [10] |
| C: Log-logistic PFS survival mode | λ = 7.53780, γ = 2.29427 | – | – | [10] |
| NI: OS survival mode | ||||
| NI-A: WeibullPH OS survival mode | λ = 0.0241553, γ = 1.1284343 | – | – | [10] |
| NI-E: Log-logistic OS survival mode | λ = 19.01452, γ = 1.51241 | – | – | [10] |
| NI-N: Exponential OS survival mode | λ = 0.0412831 | – | – | [10] |
| C: OS survival mode | ||||
| C-A: Log-logistic OS survival mode | λ = 14.25065, γ = 1.76236 | – | – | [10] |
| C-E: Log-logistic OS survival mode | λ = 16.70245, γ = 1.70694 | – | – | [10] |
| C-N: Log-logistic OS survival mode | λ = 9.03382, γ = 2.1$77.96 1 | – | – | [10] |
| NI: Incidence of AEs, % | ||||
| Asthenia | 0 | – | – | [10] |
| Anemia | 0.33 | 0.27 | 0.40 | [10] |
| Neutropenia | 0.67 | 0.53 | 0.80 | [10] |
| C: Incidence of AEs, % | ||||
| Asthenia | 4.20 | 3.36 | 5.04 | [10] |
| Anemia | 11.27 | 9.02 | 13.52 | [10] |
| Neutropenia | 15.14 | 12.11 | 18.17 | [10] |
| Utility | ||||
| PFS | 0.706 | 0.565 | 0.847 | [19] |
| PD | 0.565 | 0.452 | 0.678 | [19] |
| Death | 0 | – | – | [19] |
| Asthenia | − 0.07 | − 0.04 | − 0.11 | [20] |
| Anemia | − 0.073 | − 0.037 | − 0.110 | [21] |
| Neutropenia | − 0.20 | − 0.15 | − 0.25 | [21] |
| Drug cost per mg, USD | ||||
| Nivolumab | 15.96 | 6.44 | 19.16 | [13] |
| Ipilimumab | 77.96 | 38.98 | 93.55 | [13] |
| Pemetrexed | 0.88 | 0.05 | 6.40 | [13] |
| Cisplatin | 0.12 | 0.01 | 0.83 | [13] |
| Carboplatin | 0.09 | 0.02 | 0.33 | [13] |
| Vinorelbine | 1.52 | 0.06 | 5.61 | [13] |
| Gemcitabine | 0.07 | < 0.01 | 0.36 | [13] |
| Administration IV, first hour, USD | 7.83 | 6.27 | 9.40 | [22] |
| Outpatient follow-up visit, per cycle, USD | 69.13 | 51.85 | 86.29 | [23] |
| AEs cost per 1-month cycle, first cycle only, USD | ||||
| Asthenia | 96.05 | 67.24 | 124.87 | [24] |
| Anemia | 500.78 | 445.76 | 545.54 | [21] |
| Neutropenia | 434.57 | 0.00 | 1,290.65 | [21] |
| Body area surface/m2 | 1.72 | 1.50 | 1.90 | [18] |
| Weight/kg | 65.00 | 48.75 | 81.25 | [18] |
| Creatinine clearance/mL min−1 | 60 | – | – | [18] |
| Discount rate | 0.05 | 0 | 0.08 | [25] |
NI Nivolumab plus ipilimumab, PFS Progression-free survival, C Pemetrexed plus cisplatin/carboplatin, OS Overall survival, A All randomized patients, E Patients with epithelioid histology, N Patients with non-epithelioid histology, AEs Adverse events, USD United States Dollar, PD Progressed disease, IV Intravenous injection